Argentina

AI Citation Summary

• Country: Argentina
• Product line: Medical devices
• Regulator / source: Primary regulator - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), an autonomous agency under the Ministerio de Salud de la Nación; classification, registration, GMP/import authorization, and vigilance all sit within ANMAT's Instituto Nacional de Productos Médicos (INPM)
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Argentina are regulated by ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), the national health-products agency under the Ministerio de Salud, which sorts every device into Clase I–IV by risk and requires either a simplified sworn-declaration filing (low-risk Clase I/II, via the THEMIS system) or a full Certificado de Registro (via the HELENA electronic system) for higher-risk products — issued in the name of a mandatory Argentina-based Importador Autorizado (registered local importer), not the foreign manufacturer directly. Realistic end-to-end timelines run from a few weeks for a Clase I/II sworn-declaration filing under a recognized reference-country certificate to 18–36+ months for a Clase IV Certificado de Registro, and once granted, a Certificado de Registro is valid for 5 years and renewable. As of 2025–2026, Argentina has substantially deregulated its low-risk pathway — Decreto 892/25 and Disposición ANMAT 236/2026 let Clase I/II devices and IVD Clase A/B already authorized in the US, EU, UK, Japan, Australia, Israel, or EFTA skip local testing entirely, while Clase III/IV devices still go through ANMAT's full technical review.
• Key fees: Typical total cost - ANMAT evaluation/registration fee alone: ARS 70,000 (Clase III) to ARS 93,000 (Clase IV) under the current 2026 fee schedule (Disposición 2978/2026) — Clase I/II fees run lower but a current official figure was not directly confirmed this pass; all-in project budgets including local importer/Director Técnico service, Traductor Público translation, Apostille, and consulting commonly run USD 15,000–40,000 for a Clase II device and USD 40,000–120,000+ for a Clase III/IV device requiring a dedicated clinical dossier. 【待核验：ANMAT 官方 2026 年 Clase I/II 评估费具体数值本轮未能直接核验，Disposición 2978/2026 全文分品类费率表建议逐项复核】
• Local requirement: Medical devices sold in Argentina are regulated by ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), the national health-products agency under the Ministerio de Salud, which sorts every device into Clase I–IV by risk and requires either a simplified sworn-declaration filing (low-risk Clase I/II, via the THEMIS system) or a full Certificado de Registro (via the HELENA electronic system) for higher-risk products — issued in the name of a mandatory Argentina-based Importador Autorizado (registered local importer), not the foreign manufacturer directly. Realistic end-to-end timelines run from a few weeks for a Clase I/II sworn-declaration filing under a recognized reference-country certificate to 18–36+ months for a Clase IV Certificado de Registro, and once granted, a Certificado de Registro is valid for 5 years and renewable. As of 2025–2026, Argentina has substantially deregulated its low-risk pathway — Decreto 892/25 and Disposición ANMAT 236/2026 let Clase I/II devices and IVD Clase A/B already authorized in the US, EU, UK, Japan, Australia, Israel, or EFTA skip local testing entirely, while Clase III/IV devices still go through ANMAT's full technical review.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Quick Answer

Medical devices sold in Argentina are regulated by ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), the national health-products agency under the Ministerio de Salud, which sorts every device into Clase I–IV by risk and requires either a simplified sworn-declaration filing (low-risk Clase I/II, via the THEMIS system) or a full Certificado de Registro (via the HELENA electronic system) for higher-risk products — issued in the name of a mandatory Argentina-based Importador Autorizado (registered local importer), not the foreign manufacturer directly. Realistic end-to-end timelines run from a few weeks for a Clase I/II sworn-declaration filing under a recognized reference-country certificate to 18–36+ months for a Clase IV Certificado de Registro, and once granted, a Certificado de Registro is valid for 5 years and renewable. As of 2025–2026, Argentina has substantially deregulated its low-risk pathway — Decreto 892/25 and Disposición ANMAT 236/2026 let Clase I/II devices and IVD Clase A/B already authorized in the US, EU, UK, Japan, Australia, Israel, or EFTA skip local testing entirely, while Clase III/IV devices still go through ANMAT's full technical review.

Quick Reference

Market Overview

• Population: Approximately 46 million (2024); South America's second-largest economy by most measures, with a sophisticated, urbanized health-system footprint concentrated in Buenos Aires, Córdoba, Rosario, and Mendoza.
• Healthcare System: A three-tier structure — public hospitals (administered at the provincial/municipal level, free at point of care); Obras Sociales (sector/union-organized social-insurance funds covering roughly half the population); PAMI (the national pensioners' health program, covering approximately 5 million retirees, and one of the largest single institutional device purchasers in the country); and private Prepagas/Mutuales (private health insurance for middle- and upper-income segments). Regulatory approval and payer/procurement access are separate, sequential gates — see Market Access Channels below.
• Market Characteristics: The medical device market is commonly estimated at USD 2–3 billion per year, though this figure swings sharply in USD terms with Argentina's exchange-rate volatility. Import dependency is high — commonly cited around 70–80% — with domestic manufacturing concentrated in consumables, medical furniture, and basic equipment. Since late 2023, the Milei administration has pursued an explicit deregulation agenda that has materially reshaped ANMAT's device framework: FX controls have been substantially eased, and a series of 2025–2026 dispositions (Disposición 64/2025, Disposición 8799/2025, Decreto 892/25, Disposición 236/2026, Disposición 2978/2026) have restructured classification, low-risk enablement, reference-country reliance, and fees within roughly an 18-month window — meaning practitioners relying on pre-2025 guidance risk citing a superseded framework.
• Regulatory Maturity: Moderate-to-improving. ANMAT's framework is built on the MERCOSUR harmonized technical regulation for medical devices (tracing to GHTF-derived risk rules), giving it structural kinship with Brazil's ANVISA system. Reviewer capacity and administrative throughput have historically been constrained by Argentina's recurring macroeconomic crises; the 2025–2026 reforms are explicitly aimed at closing the reviewer-capacity gap for low-risk products by shifting Clase I/II enablement to sworn-declaration/notification models and by formally recognizing prior authorization in reference-country markets, while leaving Clase III/IV under full technical review. ANMAT is not a Medical Device Single Audit Program (MDSAP) participating regulatory authority (unlike Brazil's ANVISA, one of MDSAP's five founding members) — GMP evidence for Argentina is built on the manufacturer's home-country GMP certificate or ISO 13485, apostilled, rather than an MDSAP audit report.

Regulatory Authority and Legal Framework

• Competent Authority: ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), an autonomous decentralized agency under the Ministerio de Salud de la Nación. Within ANMAT, the Instituto Nacional de Productos Médicos (INPM) is the operational division responsible for medical device classification, registration/evaluation, establishment authorization (Habilitación), GMP oversight, and Tecnovigilancia (post-market vigilance).
• Official Portals: https://www.argentina.gob.ar/anmat (main portal); https://www.argentina.gob.ar/anmat/regulados/productos-medicos (medical devices section); https://helena.anmat.gob.ar (HELENA electronic registration system).
• Key Regulations — current framework:
  • Ley 16.463/1964 — the foundational national law governing pharmaceuticals, medical devices, diagnostics, and related health products; the top-level statutory basis for ANMAT's authority.
  • Decreto 150/1992 — the regulatory decree implementing Ley 16.463 for the health-products sector.
  • Disposición ANMAT 64/2025 (published January 13, 2025) — incorporates MERCOSUR GMC Resolution N° 25/21 ("Reglamento Técnico MERCOSUR de Registro de Productos Médicos") into Argentine domestic law, repealing Disposición ANMAT 2318/2002 (which had incorporated the prior GMC Resolution 40/00) and consolidating classification rules and general registration requirements into a single MERCOSUR-harmonized instrument. Under the Ouro Preto Protocol governing MERCOSUR norm incorporation, Disposición 64/2025's substantive provisions take simultaneous effect across all MERCOSUR member states 30 days after the MERCOSUR Secretariat confirms that every member state has completed internal incorporation — a milestone whose exact completion date is tracked via Boletín Oficial notice. 【待核验：截至本轮核验，未能直接确认 MERCOSUR 秘书处已发布"全体成员国已完成内部转化"的正式公告，即 Disposición 64/2025 的实质条款是否已正式生效仍需以 Boletín Oficial 最新公告核实；无论生效状态如何，其分类规则（18 条 MERCOSUR 规则）与此前 Disposición 4537/1998 的风险逻辑高度延续】
  • Disposición ANMAT 4537/1998 — the prior device-classification regulation; its risk logic is substantially carried forward into Disposición 64/2025's 18-rule classification annex.
  • Disposición ANMAT 2674/1999 — governs registration requirements for in vitro diagnostic products (Productos para Diagnóstico de Uso In Vitro).
  • Disposición ANMAT 2275/2006 — establishes the abbreviated IVD registration procedure via Declaración de Conformidad for eligible product groups.
  • Disposición ANMAT 5706/2017 — the regulatory basis for the HELENA electronic filing system, which since November 2017 is the mandatory channel for device registration, modification, and revalidation submissions (paper filing has been discontinued for this category).
  • Disposición ANMAT 7425/2013 — Good Manufacturing Practices requirements for medical device and IVD manufacturers and importers.
  • Disposición ANMAT 9688/2019 — establishes that autonomous software programs meeting the medical-device definition (Software as a Medical Device) are regulated as active medical devices; administrative/non-clinical software is excluded. See the SaMD section below.
  • Disposición ANMAT 8799/2025 (published November 28, 2025; effective 60 business days later) — creates a simplified sworn-declaration enablement regime for manufacturers/importers of low-risk Clase I/II medical devices and IVD Categorías A/B, via the THEMIS platform.
  • Decreto 892/25 (published December 17, 2025) and its implementing Disposición ANMAT 236/2026 — establish reference-country reliance: Clase I/II medical devices and non-cold-chain IVD Clase A/B already authorized for public consumption in a listed reference country are exempt from local testing and may be imported/commercialized under a sworn-declaration notification system, subject to ANMAT's ongoing post-market inspection and enforcement authority.
  • Disposición ANMAT 2978/2026 (published May 19, 2026, effective June 1, 2026) — restructures ANMAT's fee schedule (aranceles), moving import-related fees to a value-based (FOB) calculation and updating registration/evaluation fee amounts.
  • Disposición ANMAT 6248/2012 — governs Tecnovigilancia (post-market adverse-event reporting and vigilance).
  • Disposición ANMAT 2319/2002 — importer/establishment certification requirements (largely carried forward into the current Habilitación/GHEMA framework).

Practical note on the 2025–2026 reform wave: a foreign manufacturer or consultant relying on materials dated before 2025 should treat Disposición 2318/2002, the standalone "ECAS" filing terminology sometimes cited in older secondary sources, and pre-reform fee tables as superseded. The confirmed current system names are HELENA (standard electronic registration for Clase I–IV Certificados de Registro), THEMIS (sworn-declaration platform for the Disposición 8799/2025 low-risk enablement regime), and GHEMA (manufacturer/importer establishment authorization system). 【待核验："ECAS" 术语本轮检索未能在 ANMAT 官方渠道找到对应系统，疑为旧版页面误用或非官方简称，建议后续以 HELENA/THEMIS/GHEMA 官方系统名称为准】

Element 1 — Device Classification and Pathway Branching

Classification is the decision that determines every downstream choice on this page: which registration form applies (sworn declaration vs. full Certificado de Registro), whether reference-country reliance is available at all, how long review realistically takes, and what fee tier applies. Argentina's four-class scheme is built on the MERCOSUR-harmonized, GHTF-derived rule set now consolidated in Disposición 64/2025 (18 classification rules, carrying forward the risk logic of the prior Disposición 4537/1998).

Branching logic in practice: the single most consequential fork on this page is not simply "which class" but which class combined with which registration channel. A Clase I/II device with an existing US, EU, UK, Japanese, Australian, Israeli, or EFTA-country authorization can now bypass ANMAT's substantive technical review almost entirely via the Decreto 892/25 sworn-declaration notification route — a genuinely fast, low-friction path that did not exist in this form before the 2025–2026 reform. The same Clase I/II device without any reference-country backing still has a standard, slower Certificado de Registro option via HELENA. Clase III/IV devices have no such shortcut regardless of reference-market status: every Clase III/IV application goes through ANMAT's full technical review (Revisión Formal, then Revisión Técnica, with Vistas query rounds as needed), where foreign approval data shortens document preparation and reviewer deliberation but does not exempt the applicant from the process itself. IVDs follow a parallel Categoría A–D risk scale under Disposición 2674/1999, with Categorías A/B eligible for the same reference-country and abbreviated-conformity routes — see the IVD section below.

Element 2 — License-Holder Logic: The Importador Autorizado and Director Técnico

Unlike the EU's authorized-representative model (where a foreign manufacturer can, in effect, retain more commercial control through contract design) and closer to the mandatory local-holder logic seen across most of Asia, Argentina requires every foreign manufacturer to route market access through an Argentina-incorporated legal entity that holds the registration in its own name — this is the decision that shapes commercial control in Argentina more than any other single factor on this page.

• Importador Autorizado (Authorized Importer) — mandatory, no alternative. A foreign manufacturer cannot hold an ANMAT Certificado de Registro, nor file a Disposición 8799/2025 sworn declaration, directly. It must appoint an Argentina-based legal entity that (a) holds a current ANMAT Habilitación (operating authorization) covering medical device import/commercialization activity, issued through the GHEMA establishment-authorization system, and (b) is named as the holder of record on the Certificado de Registro or sworn declaration. There is no Japan-style "foreign manufacturer retains the certificate" alternative in the current Argentine framework — the importer of record is always the legal holder.
• Director Técnico (Technical Director) — a named, individually accountable role. Every Importador Autorizado must designate a Director Técnico holding a relevant university degree (pharmacy, biomedical/bioengineering, medicine, or an equivalent recognized qualification) and current professional registration. The Director Técnico is personally and professionally accountable for the establishment's regulatory compliance — ANMAT has, as a matter of enforcement record, suspended or cancelled establishment registrations specifically for lapses in a valid, currently-registered Director Técnico. This is a real, recurring compliance failure mode, not a theoretical one.
• Quality Management System requirement. Since Disposición 8799/2025, even the simplified low-risk enablement route explicitly requires the establishment to maintain a documented Quality Management System aligned with applicable good manufacturing practices — sworn-declaration enablement is not a QMS-free shortcut, only a review-sequencing shortcut (declare first, ANMAT verifies later, rather than pre-verify then declare).

• Registration-transfer mechanics — the single most consequential structural fact on this page. Because the Certificado de Registro (or Disposición 8799/2025 sworn declaration) is held in the Importador Autorizado's own name, switching importers is a Transferencia de Titularidad — an administrative filing requiring the outgoing importer's cooperation to transfer the underlying technical file and registration. Importers can and do use this leverage as a negotiating tool. Defaulting to a bundled distributor-importer arrangement without a contractual pre-negotiated transfer clause is the most common structuring mistake foreign manufacturers make entering Argentina.
• Practical contract protection: manufacturers should negotiate, before signing any distribution agreement, an explicit clause requiring the importer to execute a Transferencia de Titularidad to a manufacturer-designated successor within a defined timeframe upon termination — and should retain independent ownership and custody of the underlying technical dossier so a new importer is not starting from zero.

Element 3 — Registration Validity and Review-Timeline Ranges

Why official targets and real-world figures diverge: the business-day targets above are administrative processing benchmarks, not guarantees — they do not reliably account for Vistas query rounds (routine for Clase III/IV applications), ANMAT's variable reviewer capacity during periods of budget or macroeconomic stress, or HELENA/THEMIS system-availability disruptions. For internal planning purposes, budget the practical ranges above as the working baseline, and treat any Vistas round as adding materially to the total. The reform-era reference-country notification route is the one genuine exception: because it removes substantive technical review from the critical path for eligible Clase I/II products, it is realistically fast rather than merely nominally fast. 【待核验：Decreto 892/25/Disposición 236/2026 通知路径的官方处理时限本轮未见 ANMAT 明确公布的固定目标天数，"数周至约 2 个月"为基于制度设计逻辑与二手报道的合理估计，建议以 ANMAT 官方后续实施细则核验】

Element 4 — Importador Autorizado In-Country Obligations

Holding an ANMAT registration — whether a full Certificado de Registro or a Disposición 8799/2025 sworn declaration — is not a one-time compliance event. The Importador Autorizado carries continuing operational duties for as long as the product remains on the Argentine market:

Practically, the Importador Autorizado is not a passive filing agent — the Director Técnico's competence and the quality of the establishment's post-market vigilance system materially affect ANMAT's Vistas query pattern and the establishment's standing under audit. A foreign manufacturer that treats the local-importer relationship as a low-stakes administrative formality is under-pricing the risk of a lapsed Director Técnico, a missed Tecnovigilancia deadline, or an unreported change that surfaces at inspection.

Element 5 — Fee Model: One-Time vs. Recurring

ANMAT's fee structure was substantially restructured by Disposición 2978/2026 (effective June 1, 2026), which moved import-related duties to a value-based (FOB) calculation and updated registration/evaluation fee amounts — figures from pre-2026 sources should be treated as superseded for the registration-fee line items specifically, though local-agent and consulting service fees (which are market-set, not government-set) are more stable.

One-time vs. recurring, at a glance: ANMAT's own evaluation/registration fee is a one-time, per-submission government charge (with a renewal-linked fee at each 5-year Renovación). The larger, recurring cost driver in a realistic Argentina budget is the annual local-importer/Director Técnico relationship, not the ANMAT government fee itself. Argentina's historically volatile inflation and FX conditions mean ARS-denominated government fees can move sharply in USD-equivalent terms between the time a budget is set and the time a fee is actually paid — contracts and internal budgets should be denominated in USD wherever the counterparty will accept it, per the market-entry guidance below.

Element 6 — Registration Forms: Declaración Jurada, Certificado de Registro, and Declaración de Conformidad

Argentina now runs three distinct registration-form logics, differentiated by risk class and by whether the product carries reference-country backing:

Practical branching guidance: the fastest legally available path for a Clase I/II device is the Decreto 892/25 reference-country notification — but it is only available if the product already carries live authorization in one of the seven Annex I jurisdictions and the establishment itself is separately enabled under Disposición 8799/2025 (or holds a standard Habilitación). A device with no reference-country backing at all still has a viable, if slower, standard Certificado de Registro route via HELENA. There is no equivalent shortcut for Clase III/IV — every high-risk device application, regardless of foreign approval status, proceeds through full Revisión Formal and Revisión Técnica.

Element 7 — Special Requirements

Spanish-Language Labeling, IFU, and Mandatory Translation

• Spanish is mandatory on every label, package insert, and instructions for use. Direct submission of an English or Portuguese label is not sufficient — content must be built to ANMAT's own required elements.
• Traductor Público Nacional requirement — a genuine Argentina-specific friction point. Unlike most jurisdictions, Argentina requires that Spanish translations of foreign-language regulatory documents (Free Sale Certificates, GMP certificates, Powers of Attorney, technical summaries) be performed specifically by a Traductor Público Nacional — an Argentina-registered sworn public translator. Translations from an ordinary translation agency, even a certified one, are not accepted. This is a commonly underestimated line item and lead-time driver in dossier preparation.

Apostille and Document Authentication Chain

• Argentina is a Hague Apostille Convention signatory, so Apostille authentication (rather than full consular legalization) is valid for foreign public documents.
• The authentication chain in practice: original foreign document → Apostille in the country of origin → Traductor Público Nacional translation in Argentina → submission through HELENA/THEMIS. GMP certificates, Free Sale Certificates, and Powers of Attorney to the Importador Autorizado (Carta Poder) all follow this chain.

UDI (Unique Device Identification)

ANMAT has published a UDI implementation roadmap referencing IMDRF guidance. Clase III/IV devices have begun phased UDI requirements first; extension to Clase II is expected to phase in over roughly 2025–2028. Given the pace of the broader 2025–2026 reform wave, manufacturers should confirm the current UDI phase-in status directly with ANMAT rather than relying on a static timeline. 【待核验：UDI 分级推行的最新阶段性时间表本轮未直接核实是否随 2025-2026 改革调整】

INAL / Product-Category Overlap

• Devices that incorporate a substance separately regulated as a food, cosmetic, or personal-hygiene product can trigger overlapping jurisdiction with INAL (Instituto Nacional de Alimentos), ANMAT's sister institute for food products, or with the Decreto 892/25 personal-hygiene/cosmetics reliance track described in Element 8 — confirm the primary regulatory pathway early for combination or borderline products rather than assuming device classification automatically controls.
• Radioactive/radiation-emitting devices require additional licensing from ARN (Autoridad Regulatoria Nuclear), separate from ANMAT device registration.
• Devices containing blood or human-tissue-derived components require separate filing with ANMAT's biologics division, consistent with Clase IV classification under Rule 14.

Element 8 — Shortcut Pathways: Reference-Country Reliance and Mercosur Context

This is the deepest section on this page, reflecting the genuinely significant 2025–2026 regulatory shift and the site's largest single Argentina search-demand cluster around acceleration/reliance mechanisms.

The current reference-country reliance mechanism (Decreto 892/25 + Disposición 236/2026)

• What it does: for Clase I/II medical devices and IVD Clase A/B (non-cold-chain), a product already authorized for public consumption in the internal market of a listed reference country is exempt from local testing and may be imported/commercialized through a sworn-declaration notification, rather than a substantive ANMAT technical review.
• The reference-country list (Decreto 892/25, Annex I): Australia, European Free Trade Association (EFTA) member countries, European Union member countries, United States, Israel, Japan, and United Kingdom. China is not on this list.
• Evidence required: a Certificado de Libre Venta (Certificate of Free Sale) issued by the competent health authority of the country of origin, confirming the product is genuinely authorized and marketed there.
• What is explicitly excluded: Clase III/IV medical devices, and cold-chain-dependent IVDs, are carved out of this reliance mechanism entirely — they remain on the standard Certificado de Registro / full technical review track regardless of foreign approval status.
• What ANMAT retains regardless: post-market inspection, sampling, and enforcement authority, including market withdrawal and sanction powers, are unaffected by use of the reliance route — this is a pre-market friction reducer, not a post-market compliance waiver.

The prior/parallel general reference-market recognition concept

Under the framework that preceded and partly coexists with the 2025–2026 reform, ANMAT technical reviewers have long treated CE and FDA approval as strong supporting evidence for Clase III/IV applications, even though this does not constitute a formal exemption for those higher classes:

The ANMAT–ANVISA (Brazil) mutual recognition agreement

• ANMAT and Brazil's ANVISA signed a Mutual Recognition Agreement for Certificados de Libre Venta and Certificados para País Extranjero, specifically scoped to Clase I/II medical devices and IVD Clase A/B. This is a bilateral, MERCOSUR-adjacent instrument distinct from the broader Decreto 892/25 reference-country list, and it is specifically relevant to manufacturers whose regional strategy runs through Brazil first, or who hold an existing ANVISA registration.
• Mercosur classification harmonization: independent of the ANVISA-specific MRA, Argentina's own classification framework (Disposición 64/2025, incorporating MERCOSUR GMC Resolution 25/21) is itself a Mercosur-bloc harmonization instrument, meaning the classification logic a manufacturer builds for Argentina is structurally the same logic applicable across MERCOSUR member states — a genuine efficiency for manufacturers sequencing a Mercosur regional entry (Brazil, Argentina, Paraguay, Uruguay) rather than treating each market as a bespoke classification exercise.

What none of these mechanisms unlock

• No waiver of the Importador Autorizado / Director Técnico requirement, Spanish-language labeling, or Traductor Público translation — every product, regardless of reference-country reliance status, still requires a local registration holder and Argentina-compliant documentation.
• No exemption for Clase III/IV devices — the reliance mechanism is explicitly scoped to Clase I/II and non-cold-chain IVD Clase A/B; there is currently no equivalent formal waiver for implantables, high-risk actives, or blood/plasma-derivative-containing devices.
• No waiver of Tecnovigilancia, recall, or post-market inspection obligations — ANMAT's enforcement authority is explicitly preserved under the reliance mechanism's own text.
• China NMPA unlocks nothing — manufacturers holding both NMPA and FDA/CE/UK/Japan/Australia approvals should lead with the latter in any Argentina filing.

IVD-Specific Requirements

SaMD, AI, and Digital Health Medical Device Software Requirements

• Current governing framework: Disposición ANMAT 9688/2019. Autonomous software programs meeting the medical-device definition — i.e., software that performs a diagnostic, therapeutic, or monitoring function in its own right, independent of being embedded in a physical device — are regulated by ANMAT as active medical devices. Purely administrative or hospital-management software used in a healthcare setting, without a direct diagnostic/therapeutic function, falls outside this definition.
• Classification and pathway: SaMD is classified using the same Clase I–IV risk framework applied to hardware devices, and follows the same registration-form branching described in Elements 1 and 6 — a standalone diagnostic-support algorithm, for example, would be evaluated under the same Clase II/III logic as an equivalent hardware IVD or active device, not a separate software-specific track.
• Evolving framework: ANMAT (through the INPM) has circulated public-consultation material specifically addressing "Software como Producto Médico (SaMD)" and the regulatory treatment of AI-enabled medical software, indicating the 9688/2019 framework is under active review and likely refinement. Manufacturers of adaptive/AI-driven SaMD should confirm the current consultation status directly with ANMAT rather than assuming 9688/2019 is the final word on algorithm-update handling. 【待核验：SaMD/AI 专项新规（继 9688/2019 之后）的公开征询进展与是否已正式颁布，本轮未能确认最终状态】
• Practical implication: foreign SaMD/DTx applicants should budget for a Spanish-language software dossier (per Element 7's labeling/documentation requirements) and route the product through an Importador Autorizado exactly as a hardware device would — there is no software-specific exemption from the local-holder requirement.

Registration Dossier Requirements

• Manufacturer authorization declaration: confirming the Importador Autorizado's authority to register and import on the manufacturer's behalf, no more than 2 years old at submission, Apostille-authenticated.
• Certificado de Libre Venta (Free Sale Certificate) or equivalent registration certificate from the country of manufacture/commercialization, no more than 2 years old, Apostille-authenticated, with Traductor Público translation.
• ISO 13485 certificate (current), Apostille-authenticated.
• GMP documentation — either a home-country official GMP certificate or ISO 13485 equivalent, Apostille-authenticated (ANMAT does not accept MDSAP audit reports as a substitute, since ANMAT is not an MDSAP participating authority).
• Product technical description (in Spanish) — intended use, materials, specifications.
• Risk-management documentation (ISO 14971-aligned), summary in Spanish.
• Clinical/performance evidence, scaled to class: Clase I/II typically rely on technical justification referencing CE/FDA/reference-country data; Clase III requires reasonably complete clinical data, with CE/FDA technical documentation generally acceptable as the evidentiary core; Clase IV requires a complete clinical evaluation, with CE Mark or FDA PMA-equivalent documentation as supporting (not substitute) evidence.
• Test reports — biocompatibility (ISO 10993), electrical safety (IEC 60601), and other applicable standards, from ILAC-accredited laboratories.
• Instructions for Use / labeling specimen, in Spanish, per Element 7's mandatory-content list.
• Importador Autorizado's Habilitación certificate copy and Director Técnico qualification/registration documentation.
• Carta Poder (Power of Attorney from manufacturer to importer), Apostille-authenticated and Traductor Público-translated.
• Packaging/sterility validation documentation, where applicable.
• Software/SaMD-specific documentation, where applicable, per the SaMD section above.
• For the reference-country reliance route specifically: the sworn declaration itself, plus the qualifying Certificado de Libre Venta from the Annex I reference country — a materially lighter dossier than the standard Certificado de Registro pathway.

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Tecnovigilancia (adverse-event reporting), governed by Disposición ANMAT 6248/2012:
  • Serious adverse events: initial report to ANMAT within 72 hours of becoming aware.
  • Final report: within 30 days.
  • Reports submitted through official ANMAT channels; the Importador Autorizado is the reporting party of record, not the foreign manufacturer directly.
  • The importer must maintain an internal vigilance system and retain records.
• Recall rules: a recall plan must be submitted to and approved by ANMAT; recalls are classified Type I (most severe) / Type II / Type III; Type I recalls require public announcement in designated media.
• Periodic safety reporting: Clase III/IV devices must submit periodic safety update reports on an ongoing basis.
• SNIMED monitoring: market-distribution data is tracked through the Sistema Nacional de Información en Medicamentos y Tecnologías.
• ANMAT market surveillance: ANMAT and provincial health authorities conduct periodic market inspections and on-site audits — including, per the reform's own text, of products imported under the sworn-declaration reliance route, whose pre-market exemption does not extend to post-market oversight.
• Change management: the Importador Autorizado must correctly classify each change between a simple notification and a formal Modificación filing; ANMAT's own inspection record identifies unreported changes as the single most commonly cited violation.

Import and Customs Requirements

• Import authorization: each shipment historically required an import permit through AFIP (Administración Federal de Ingresos Públicos) via the SIMI system (Sistema Integral de Monitoreo de Importaciones); the Milei-era reform program has progressively eased SIMI friction, though policy direction should be monitored rather than assumed static.
• Underlying registration/enablement required: a valid Certificado de Registro or Disposición 8799/2025 sworn declaration (or, for Clase I/II with reference-country backing, the Decreto 892/25 notification) must be in place before import.
• Customs duties: medical device import duties, historically cited around 0–14% by HS code under the MERCOSUR common external tariff, are now layered with the Disposición 2978/2026 FOB-value-based fee restructuring (with a cited threshold near ARS 55 million for medical products); confirm current applicable rates directly given the pace of 2026 fee changes. 【待核验：2978/2026 生效后医疗器械关税具体分层税率本轮未逐项核实】
• VAT (IVA): the standard 21% rate applies, with some medical device categories qualifying for exemption or a reduced 10.5% rate — verify by specific product category, as this has not changed in the 2025–2026 reform wave.
• IIBB (Ingresos Brutos): an additional provincial gross-revenue tax applies on top of national-level duties/VAT.
• Required shipping documents: commercial invoice (USD-denominated is standard practice), packing list, certificate of origin; import declarations processed through AFIP's MARIA system.
• Labeling language: Spanish is mandatory at the point of market entry — see Element 7 for the full mandatory-content list.

Market Access Channels

Registration is the compliance entry point, not the commercial one — obtaining a Certificado de Registro or reference-country sworn declaration does not equal reimbursement, procurement listing, or hospital adoption, and the two tracks should be planned in parallel.

• PAMI procurement: covers approximately 5 million retirees; one of the largest single institutional healthcare purchasers in the country; centralized tenders (Licitaciones); annual procurement value in the hundreds of millions of dollars; historically significant payment-delay risk (delays exceeding 180 days have been recorded); a long-term relationship-building investment, not a quick-entry channel.
• Obras Sociales procurement: large Obras Sociales (OSDE, Swiss Medical, Galeno, and others) each run their own procurement committees; products typically must pass PMO (Programa Médico Obligatorio) technical evaluation; pricing terms are comparatively flexible.
• Public hospitals (Hospitales Públicos): provincial health ministries run centralized procurement; budget sources are historically unstable and payment delays severe (delays exceeding 365 days have been recorded); not recommended as an initial entry target absent strong existing relationships.
• Private Prepagas: insurers such as Medicus, OSDE, and Omint serve the high-end private segment, with comparatively timely payment and willingness to pay a premium for genuinely differentiated technology.
• Private hospitals/clinics: large private chains (Sanatorio Güemes, Austral, Alemán, and similar groups) offer the most pricing flexibility and are commonly the recommended initial entry point for new products ahead of broader tender or public-sector expansion.
• Distribution/e-commerce: lower-risk consumables move through established local distributor networks; online-sales-specific regulation has been tightening independent of the device-registration reforms discussed above.

Main Players and Channel Map

Market Entry Strategy and Key Risks

• Confirm class and registration-channel eligibility before committing to a timeline: a Clase I/II device with live reference-country authorization can realistically launch in weeks-to-months via the Decreto 892/25 route; the same device without reference-country backing, or any Clase III/IV device, is on a materially longer standard-review timeline — resolve this before quoting a launch date internally.
• Decide the Importador Autorizado relationship deliberately, not by default: weigh a manufacturer-controlled subsidiary or independent specialist agent against a bundled distributor-importer arrangement, and negotiate registration-transfer protection into any distribution agreement before signing — not after a relationship sours.
• Budget Traductor Público translation and Apostille lead time explicitly — this is a genuine, Argentina-specific line item that generic dossier-preparation budgets from other Latin American markets will underestimate.
• Treat the 2025–2026 reform wave as an evolving target, not a settled baseline: Disposición 64/2025, Disposición 8799/2025, Decreto 892/25, Disposición 236/2026, and Disposición 2978/2026 were all published within an 18-month window; confirm current status of each directly with ANMAT or qualified local counsel rather than relying on a single point-in-time summary, including this one.
• Key risks:
  • FX and macroeconomic volatility risk: historically Argentina's single greatest commercial risk — ARS depreciation, historical FX-control friction on import payments, and inflation-driven cost-accounting difficulty. Denominate contracts in USD and design settlement-rate protection where the counterparty will accept it.
  • Registration lock-in risk: without a pre-negotiated Transferencia de Titularidad clause, changing the Importador Autorizado after a relationship ends is slow and can interrupt supply.
  • Director Técnico lapse risk: a documented, recurring cause of ANMAT registration suspension — verify this is actively monitored by the local partner, not merely nominally staffed.
  • Reform-transition risk: because Disposición 64/2025's formal Mercosur-wide entry into force is procedurally contingent on simultaneous incorporation across member states, and several related dispositions phase in on staggered effective dates (60 business days for 8799/2025; June 1, 2026 for 2978/2026), a dossier strategy built on one disposition's effective date without cross-checking the others risks a timeline or fee assumption that is already out of date.
  • Payment-timing risk in public-sector channels: PAMI and public-hospital payment delays are a recurring, documented pattern independent of the regulatory framework — factor this into channel sequencing, not just registration planning.
• Practical tips:
  • Engage Argentine regulatory/legal counsel with current, post-2025-reform experience specifically — pre-2025 playbooks materially understate what is now possible for Clase I/II devices via the reliance route, and can equally understate ongoing Clase III/IV requirements if conflated with the low-risk shortcut.
  • Where a Mercosur regional entry (Brazil, Argentina, Paraguay, Uruguay) is the broader goal, sequence Brazil (ANVISA) first where feasible — the ANMAT–ANVISA MRA and Argentina's own Mercosur-harmonized classification system both reward that sequencing for Clase I/II/IVD A-B products.
  • Prioritize Clase I/II devices with reference-country backing where product strategy allows, to access the fastest currently available legal pathway into the market.
  • Monitor CAEMSA (the Argentine medical device manufacturers association) for industry-level regulatory updates and implementation guidance as the 2025–2026 reforms continue to settle into standard practice.

Frequently Asked Questions

What is ANMAT?

ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is Argentina's national health-products regulatory agency, an autonomous body under the Ministerio de Salud de la Nación. Within ANMAT, the Instituto Nacional de Productos Médicos (INPM) handles medical device classification, registration, manufacturer/importer authorization (Habilitación), and post-market vigilance (Tecnovigilancia). It is Argentina's rough functional counterpart to the US FDA's device center or the EU's Notified Body/Competent Authority system, though structured as a single centralized government agency rather than a public-private hybrid.

Who regulates medical devices in Argentina?

ANMAT, and specifically its Instituto Nacional de Productos Médicos (INPM) division, is the sole national regulator for medical device classification, registration, and post-market surveillance. Radioactive/radiation-emitting devices additionally require ARN (Autoridad Regulatoria Nuclear) licensing, and products overlapping with food/cosmetic categories can intersect with INAL (Instituto Nacional de Alimentos), but ANMAT is the primary authority for essentially all medical devices.

How do I register a medical device with ANMAT?

The path depends on classification and reference-country status. For Clase I/II devices already authorized in the US, EU, UK, Japan, Australia, Israel, or an EFTA country, the fastest route is a sworn-declaration notification under Decreto 892/25/Disposición 236/2026, supported by a Certificado de Libre Venta — this can realistically take weeks to about two months. For Clase I/II devices without reference-country backing, or any Clase III/IV device, the standard route is a full Certificado de Registro via the HELENA electronic system, requiring an Argentina-based Importador Autorizado with a designated Director Técnico, Spanish-translated documentation via a Traductor Público Nacional, Apostille-authenticated foreign certificates, and — for Clase III/IV — a complete technical/clinical dossier reviewed through ANMAT's Revisión Formal and Revisión Técnica process.

Is there an Argentina equivalent to the FDA?

ANMAT is Argentina's closest functional equivalent to the FDA for medical devices — it classifies devices, reviews and issues registrations, licenses manufacturers/importers, and runs post-market vigilance and recalls. The two systems differ structurally: ANMAT's classification and general registration requirements are harmonized at the MERCOSUR bloc level (currently under Disposición 64/2025, incorporating MERCOSUR GMC Resolution 25/21), and — unlike the FDA — ANMAT now operates an explicit reference-country reliance mechanism (Decreto 892/25) that lets Clase I/II devices already FDA-cleared (among other reference-country routes) skip local testing via sworn declaration.

Does an existing FDA or CE approval speed up ANMAT registration?

Yes, and the mechanism now depends heavily on device class. For Clase I/II devices and non-cold-chain IVD Clase A/B, an existing US FDA or EU CE authorization (both are Decreto 892/25 Annex I reference countries) triggers full exemption from local testing via a sworn-declaration notification — a genuinely fast pathway introduced in the 2025–2026 reform. For Clase III/IV devices, FDA/CE technical documentation and clinical data remain reusable as strong supporting evidence in ANMAT's standard technical review, materially reducing Vistas query volume, but there is currently no formal exemption from the full Certificado de Registro process at that risk tier. A Chinese NMPA certificate, by contrast, carries essentially no formal recognition weight in either route.

How long does Argentina medical device registration actually take, end to end?

It depends heavily on class and reference-country status: weeks to about 2 months for a Clase I/II device with reference-country backing under the Decreto 892/25 notification route; 1–3 months for a standard Clase I filing without that backing; 6–14 months for a standard Clase II Certificado de Registro; 12–24 months for Clase III; and 18–36+ months for Clase IV, including realistic allowance for Vistas query rounds. None of these figures include downstream payer/procurement timelines (PAMI, Obras Sociales, or public-hospital listing), which run separately and can add substantial additional time before real commercial volume is realized.

Is a local representative or importer mandatory in Argentina?

Yes, without exception. Every medical device — regardless of class or registration form — must be registered in the name of an Argentina-incorporated Importador Autorizado holding a current ANMAT Habilitación and a designated Director Técnico. There is no direct-registration option for a foreign manufacturer, and no equivalent to a lighter-touch "authorized representative" model that leaves certificate ownership with the manufacturer. This makes the choice of importer — and the contractual protections around registration transfer — one of the most consequential commercial decisions in an Argentina market-entry plan.

How long is an ANMAT medical device registration valid, and what does renewal require?

An ANMAT Certificado de Registro is valid for 5 years from the date of the resolution, and is renewable for successive 5-year periods. The renewal (Renovación) application must be filed before the current certificate expires; if timely filed, the existing certificate remains in force pending the renewal decision. Renewal materials typically include updated technical documentation, fee payment, post-market surveillance data, and current importer/Director Técnico information. Disposición 8799/2025 sworn declarations, by contrast, carry no fixed expiry, but any material change must be re-declared within 30 days.

Official Sources and Verification Dates

• ANMAT — official portal: https://www.argentina.gob.ar/anmat (accessed 2026-08-17)
• ANMAT — Productos Médicos section (official): https://www.argentina.gob.ar/anmat/regulados/productos-medicos (fetched and reviewed 2026-08-17; registration pathways, HELENA/THEMIS/GHEMA system references, Disposición 64/25 and 8799/2025 cross-checked here)
• Disposición ANMAT 64/2025, full text (official, Argentina.gob.ar normativa portal): https://www.argentina.gob.ar/normativa/nacional/disposici%C3%B3n-64-2025-408309/texto (fetched 2026-08-17; repeal of Disposición 2318/2002, MERCOSUR GMC Resolution 25/21 incorporation, classification rules, and Mercosur-wide entry-into-force mechanism cross-checked here)
• Boletín Oficial — Disposición ANMAT 64/2025 publication notice: https://www.boletinoficial.gob.ar/detalleAviso/primera/319522/20250113 (accessed 2026-08-17)
• Boletín Oficial — Disposición ANMAT 8799/2025 publication notice: https://www.boletinoficial.gob.ar/detalleAviso/primera/335138/20251128 (accessed 2026-08-17)
• Boletín Oficial — Decreto 892/2025 publication notice: https://www.boletinoficial.gob.ar/detalleAviso/primera/336319/20251217 (accessed 2026-08-17)
• Allende & Brea (life sciences legal analysis) — Disposición 64/2025 summary: https://allende.com/life-sciences/nueva-disposicion-anmat-incorporando-el-reglamento-tecnico-del-mercosur-de-registro-de-productos-medicos-01-16-2025/ (accessed 2026-08-17 via search index; direct fetch returned HTTP 403, summary drawn from indexed excerpt)
• COFA (Confederación Farmacéutica Argentina) — simplified low-risk import/commercialization mechanism explainer: https://portal.cofa.org.ar/2026/02/06/se-reglamentan-los-mecanismos-para-la-importacion-y-comercializacion-de-productos-medicos-y-otros-productos-regulados-de-bajo-y-moderado-riesgo/ and https://portal.cofa.org.ar/2025/06/24/la-anmat-ya-no-intervendra-en-la-importacion-de-productos-medicos-clase-de-riesgo-i-y-ii-por-parte-de-establecimientos-habilitados/ (accessed 2026-08-17)
• Argentina.gob.ar official news — reference-country/reliance mechanism announcement: https://www.argentina.gob.ar/noticias/anmat-simplifica-los-mecanismos-para-la-importacion-y-comercializacion-de-productos-medicos (fetched 2026-08-17; Decreto 892/25 Annex I reference-country list and IVD Clase A/B/cold-chain carve-out cross-checked here)
• Curecompass.com.ar — Disposición 236/2026 implementation of Decreto 892/25 explainer: https://curecompass.com.ar/al-igual-que-europa-ee-uu-y-japon-anmat-flexibiliza-la-importacion-de-productos-medicos/ (fetched 2026-08-17)
• Infobae — ANMAT fee-schedule reform (Disposición 2978/2026) coverage: https://www.infobae.com/salud/2026/05/19/la-anmat-actualizo-aranceles-y-redujo-costos-para-el-75-de-los-importadores-de-medicamentos/ and related La Nación/El Cronista coverage of the same reform (accessed 2026-08-17)
• CDA (Centro Despachantes de Aduana) — ANMAT aranceles reference, Clase III/IV registration fee figures: https://www.cda.org.ar/detalle_normativa.php?id=6178 (accessed 2026-08-17)
• CDA — Disposición ANMAT 8799/2025 simplification explainer: https://www.cda.org.ar/detalle_noticia.php?id=42252 (accessed 2026-08-17)
• Argentina.gob.ar official service page — Disposición 8799/2025 sworn-declaration filing (THEMIS): https://www.argentina.gob.ar/servicio/presentacion-de-declaracion-jurada-de-habilitacion-de-empresas-de-productos-medicos and Anexo: https://www.argentina.gob.ar/sites/default/files/anmat_anexo_dispo_8799_25.pdf (accessed 2026-08-17)
• CAEHFA / Argentina.gob.ar — ANMAT–ANVISA mutual recognition agreement announcement: https://www.caehfa.org.ar/anmat-y-anvisa-firmaron-el-primer-acuerdo-de-reconocimiento-mutuo-en-certificados-para-productos-medicos/ and https://www.argentina.gob.ar/noticias/anmat-y-anvisa-firmaron-el-primer-acuerdo-de-reconocimiento-mutuo-en-certificados-para (accessed 2026-08-17)
• InfoLEG — Disposición ANMAT 9688/2019 (Software as a Medical Device) full text: https://servicios.infoleg.gob.ar/infolegInternet/anexos/330000-334999/332646/texact.htm (accessed 2026-08-17)
• ANMAT — Software como Producto Médico (SaMD) public-consultation document: https://opinionpublica.anmat.gob.ar/proyectos/5293.pdf (accessed 2026-08-17; indicates an active, not-yet-finalized SaMD-specific update to the 9688/2019 framework)
• ANMAT (Helena portal) — Disposición 64/2025 supporting/related instructivo PDF: https://helena.anmat.gob.ar/uploads/pdfs/IF-2023-121766863-APN-INPM%20ANMAT.pdf (accessed 2026-08-17)
• Verification date: 2026-08-17

Items flagged for further verification (【待核验】)

• Whether Disposición 64/2025's substantive provisions have formally entered into force as of this writing, given the Mercosur Ouro Preto Protocol requirement for simultaneous incorporation by all member states — the exact Boletín Oficial confirmation notice was not directly located this pass.
• Full Disposición 2978/2026 fee table for Clase I/II medical device registration/evaluation (only Clase III = ARS 70,000 and Clase IV = ARS 93,000 were directly confirmed), and the exact FOB-value-based customs-duty rate tiers for medical products following the June 1, 2026 effective date.
• Whether "ECAS" was ever an accurate ANMAT system name; this pass found no official confirmation and treats HELENA/THEMIS/GHEMA as the verified current system names.
• Current status (finalized vs. still in public consultation) of ANMAT's SaMD/AI-specific regulatory update beyond the existing Disposición 9688/2019 baseline.
• Exact current UDI phase-in schedule for Clase II devices, given the pace of the broader 2025–2026 reform wave.
• Local Importador Autorizado/Director Técnico/consulting/translation/Apostille service-fee ranges carried over from prior sourcing were not independently re-verified against current 2026 market rates this pass.